Tower Research Capital LLC TRC Has $54,000 Position in Voyager Therapeutics, Inc. (NASDAQ:VYGR)

Tower Research Capital LLC TRC boosted its holdings in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 302.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,399 shares of the company’s stock after buying an additional 4,809 shares during the period. Tower Research Capital LLC TRC’s holdings in Voyager Therapeutics were worth $54,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of VYGR. Gladius Capital Management LP acquired a new stake in shares of Voyager Therapeutics in the 3rd quarter valued at $25,000. AJOVista LLC bought a new position in shares of Voyager Therapeutics in the fourth quarter valued at about $39,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Voyager Therapeutics in the fourth quarter valued at about $43,000. Aigen Investment Management LP bought a new position in shares of Voyager Therapeutics in the third quarter valued at about $109,000. Finally, Ascension Capital Advisors Inc. bought a new position in shares of Voyager Therapeutics in the third quarter valued at about $112,000. Institutional investors and hedge funds own 48.03% of the company’s stock.

Voyager Therapeutics Price Performance

Voyager Therapeutics stock traded up $0.05 during mid-day trading on Tuesday, hitting $7.82. 495,064 shares of the company’s stock traded hands, compared to its average volume of 888,730. The firm has a 50 day simple moving average of $8.81 and a two-hundred day simple moving average of $7.97. Voyager Therapeutics, Inc. has a fifty-two week low of $6.06 and a fifty-two week high of $14.34. The stock has a market cap of $425.33 million, a price-to-earnings ratio of 2.53 and a beta of 0.96.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings results on Wednesday, February 28th. The company reported $1.25 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.59) by $1.84. Voyager Therapeutics had a return on equity of 63.89% and a net margin of 52.93%. The business had revenue of $90.06 million during the quarter, compared to the consensus estimate of $4.95 million. On average, research analysts anticipate that Voyager Therapeutics, Inc. will post -1.64 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have weighed in on VYGR. Citigroup started coverage on Voyager Therapeutics in a report on Thursday, March 7th. They set a “buy” rating and a $16.00 price objective for the company. StockNews.com raised Voyager Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, March 9th. Guggenheim started coverage on Voyager Therapeutics in a research note on Tuesday, March 26th. They issued a “buy” rating and a $22.00 price target for the company. HC Wainwright assumed coverage on Voyager Therapeutics in a research note on Tuesday, March 19th. They issued a “buy” rating and a $30.00 price target for the company. Finally, Wells Fargo & Company upgraded Voyager Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $9.00 to $14.00 in a research report on Tuesday, January 2nd. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, Voyager Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $19.33.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.